Medondo Holding publishes presentation for Aug. 10, 2026 annual general meeting in Munich
Reuters2026/08/11 13:51- Medondo Holding AG shareholders rejected the discharge of Dr. Jürgen Rotter for fiscal 2025, with 90.49% voting no.
- Stefan Staudacher secured discharge for fiscal 2025, backed by 94.13% yes votes.
- Shareholders discharged the supervisory board for fiscal 2025, with 84.19% voting yes.
- The auditor and group auditor appointment for 2026 passed, supported by 99.93% yes votes.
- Capital measures advanced, including the cancellation of five shares and a capital reduction via share consolidation, each approved with over 83% support.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Spot bitcoin ETFs pull in $987 million last week as institutional demand recovers
Silver Price Forecast: XAG/USD dips below $66.00 and hints at a bearish “H&S”
Twice thwarted in a week! Novartis (NVS.US) fails in phase III trial for blockbuster heart disease drug, stock plummets; Amgen (AMGN.US) dragged down as well
Swiss pharmaceutical giant Novartis has suffered another clinical trial setback—within one week, the company’s second major drug candidate has failed in a late-stage study. This latest disappointment concerns its potential blockbuster heart disease drug pelacarsen.
Crypto prices
More
